GLPwatch

On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide.

J Control Release · 2022

Last updated 2026-05-28

Researchers developed a nanogel system designed to regulate blood glucose levels by releasing the diabetes drug exenatide in response to high glucose concentrations. In tests, the nanogels prolonged the drug's effects and helped restore normal blood sugar levels from high levels, maintaining stable glucose within a normal range. The system also showed high compatibility in living organisms and improved the drug's effectiveness.

AI summary of the abstract below.

JournalJ Control Release, 2022
Citations7
Relative citation ratio0.86
NIH percentile45
Molecules exenatide
Conditions studied Type 2 Diabetes

Abstract

Diabetes mellitus is a long-term chronic disease characterized by abnormal high level blood glucose (BG). An artificial closed-loop system that mimics pancreatic β-cells and releases insulin on demand has potential to improve the therapeutic efficiency of diabetes. Herein, a lectin Concanavalin A modified oxidized starch nanogel was designed to regulate glucose dynamically according to different glucose concentrations. The nanogels were formed by double cross-linking the Concanavalin A and glucose units on oxidized starch via specific binding and amide bonds to achieve the high drug loading and glucose responsiveness. The results showed that oxidized starch nanogels prolonged the half-life of antidiabetic peptide drug exenatide and released it in response to high BG concentrations. It could absorb BG at a high level and maintain glucose homeostasis. Besides, the oxidized starch nanogels performed well in recovering regular BG level from hyperglycemia state and maintaining in euglycemia state that fitted in a biological rhythm. In addition, the nanogels showed high biocompatibility in vivo and could improve plasma half-life and therapeutic efficacy of exenatide. Overall, the nanogels protected peptide drugs from degradation in plasma as a glucose-responsive platform showing a high potential for peptide drugs delivery and antidiabetic therapy.

Verbatim abstract via PubMed 36374646 ↗

Related research